- Home
- KNSA vs CELC Comparison
KNSA vs CELC Comparison
Compare KNSA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNSA | CELC |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KNSA | CELC |
|---|---|---|
| Price | $46.85 | $120.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $55.29 | ★ $107.88 |
| AVG Volume (30 Days) | 521.4K | ★ 643.5K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $38.01 | N/A |
| Revenue Next Year | $17.42 | $740.70 |
| P/E Ratio | $63.01 | ★ N/A |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $19.62 | $9.50 |
| 52 Week High | $50.03 | $125.00 |
Technical Indicators
Market Signals| Indicator | KNSA | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 57.58 |
| Support Level | $39.96 | $99.38 |
| Resistance Level | $48.61 | N/A |
| Average True Range (ATR) | 1.91 | 6.11 |
| MACD | -0.11 | 0.91 |
| Stochastic Oscillator | 46.09 | 77.26 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.